Antioxidants (Mar 2023)

Neuroprotection of NRF2 against Ferroptosis after Traumatic Brain Injury in Mice

  • Hao Cheng,
  • Pengfei Wang,
  • Ning Wang,
  • Wenwen Dong,
  • Ziyuan Chen,
  • Mingzhe Wu,
  • Ziwei Wang,
  • Ziqi Yu,
  • Dawei Guan,
  • Linlin Wang,
  • Rui Zhao

DOI
https://doi.org/10.3390/antiox12030731
Journal volume & issue
Vol. 12, no. 3
p. 731

Abstract

Read online

Ferroptosis and iron-related redox imbalance aggravate traumatic brain injury (TBI) outcomes. NRF2 is the predominant transcription factor regulating oxidative stress and neuroinflammation in TBI, but its role in iron-induced post-TBI damage is unclear. We investigated ferroptotic neuronal damage in the injured cortex and observed neurological deficits post-TBI. These were ameliorated by the iron chelator deferoxamine (DFO) in wild-type mice. In Nrf2-knockout (Nrf2−/−) mice, more sever ferroptosis and neurological deficits were detected. Dimethyl fumarate (DMF)-mediated NRF2 activation alleviated neural dysfunction in TBI mice, partly due to TBI-induced ferroptosis mitigation. Additionally, FTH-FTL and FSP1 protein levels, associated with iron metabolism and the ferroptotic redox balance, were highly NRF2-dependent post-TBI. Thus, NRF2 is neuroprotective against TBI-induced ferroptosis through both the xCT-GPX4- and FTH-FTL-determined free iron level and the FSP1-regulated redox status. This yields insights into the neuroprotective role of NRF2 in TBI-induced neuronal damage and its potential use in TBI treatment.

Keywords